No drug-related adverse events have been assessed to date in Arch Biopartners’ Phase II trial of LSALT peptide for cardiac surgery–associated acute kidney injury (CS-AKI), and a blinded data review confirms AKI events are being captured per protocol-defined KDIGO criteria. St. Michael’s Hospital in Toronto has begun dosing patients, becoming the third Canadian site actively recruiting in the 240-patient, randomized, double-blind, placebo-controlled study evaluating LSALT 10 mg IV twice daily for five days following on-pump cardiac surgery. The primary endpoint is AKI incidence within seven days.
The core development is site activation and trial execution momentum. Alongside St. Michael’s, Toronto General Hospital and the University of Calgary remain active, Royal Columbian Hospital is completing start-up, and Arch is in feasibility with three prospective U.S. centers and an additional Ontario site, with site additions gated by executed agreements. Internationally, the company is preparing final close-out visits at the first five Turkish sites that participated earlier in the study. In parallel, the investigator-led PONTiAK Phase II trial of cilastatin for nephrotoxin-induced AKI continues recruiting in Alberta, targeting 698 patients across five hospitals, with plans to create a U.S. arm; no cilastatin-related adverse events have been assessed to date in that program.
Strategically, Arch is pursuing a two-pronged AKI portfolio: a first-in-class anti-inflammatory approach via DPEP1 inhibition in a high-incidence perioperative setting, and a repurposing path with cilastatin aimed at drug-induced kidney injury. The LSALT trial design leans into operational practicality—incidence of KDIGO-defined AKI as a near-term, events-rich endpoint—while the U.S. expansion is as much about regulatory and clinical mindshare as it is about enrollment velocity. Prior LSALT clinical work in lung inflammation that showed biomarker modulation, including a significant reduction in CXCL10, gives mechanistic continuity but leaves the pivotal question—translation to reduced AKI events in cardiac surgery—unanswered.
For sites and CROs, the operational burden is nontrivial. Pre-op consent in a compressed surgical scheduling environment, perioperative coordination with anesthesia and ICU teams, and a fixed five-day IV regimen require tight workflow integration. Capturing timely creatinine measures to adjudicate KDIGO-based endpoints puts pressure on lab turnaround and EHR data quality, and discharge before day five could necessitate inpatient-to-outpatient continuity planning. U.S. participation will introduce variability in practice patterns and case mix that can stress protocol consistency but will be important for eventual regulatory engagement and payer-relevant evidence. For vendors, reliable perioperative data capture and adjudication tools will matter; for regulators, prevention claims in AKI will hinge on both incidence reduction and the signal on harder outcomes.
The next signals to watch are site activation cadence in the U.S., time to first U.S. patient, and any protocol amendments that clarify secondary endpoints such as need for renal replacement therapy, ICU or hospital length of stay, or biomarker trajectories. Recruitment risk is real in this setting—screen fails tied to off-pump conversions, consent timing, and post-op complications can slow accrual—and heterogeneity in AKI incidence across centers may dilute effect size. A clean safety profile remains necessary but not sufficient; the inflection point will be whether LSALT can demonstrate a clinically meaningful and consistent reduction in AKI events versus placebo. On the cilastatin front, the durability of enrollment in Alberta and the speed of U.S. arm formation will indicate whether the program can deliver a broad, generalizable dataset. If either study shows a robust signal, expect rapid moves toward Phase 3 planning and intensified scrutiny of manufacturing scale-up and perioperative adoption pathways.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
